Global Porcine Vaccine Market Size (2024 - 2029)

The porcine vaccine market is projected to experience growth over the forecast period, driven by increased research and development activities and the introduction of novel vaccines. Despite the temporary setbacks caused by the COVID-19 pandemic, which affected veterinary visits and research focus, the market is expected to expand due to rising product approvals and innovations aimed at addressing prevalent diseases like Porcine Reproductive and Respiratory Syndrome. However, challenges such as high storage costs and potential vaccine reactions may impede market growth.

Market Size of Global Porcine Vaccine Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Porcine Vaccines Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 2.05 Billion
Market Size (2029) USD 2.95 Billion
CAGR (2024 - 2029) 7.50 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Porcine Vaccines Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Porcine Vaccines Market Analysis

The Global Porcine Vaccine Market size is estimated at USD 2.05 billion in 2024, and is expected to reach USD 2.95 billion by 2029, growing at a CAGR of 7.5% during the forecast period (2024-2029).

The sudden outbreak of COVID-19 majorly impacted all the markets. With the focus primarily shifted to combat COVID-19, all other research and development are on hold. In July 2020, the Center for Disease Control and Prevention (CDC) provided specific guidelines to veterinary professionals for treating animals during COVID-19. Many government agencies have also recommended prioritizing urgent and emergency visits to clinics and hospitals. Furthermore, most veterinary laboratories are actively involved in testing COVID-19 in humans to overcome the global shortage of healthcare facilities and COVID-19 testing laboratories, according to the OIE (World Organization for Animal Health). However, some hospitals and clinics are taking definite measures to avoid the transmission of the virus during this pandemic situation. Prestige Animal Hospitals, for example, has taken precautionary measures when treating animals. It also launched the 'Drop Off Exams' program, which allows owners to drop off their pets for diagnosis or treatment. The results and treatment plans are then discussed through a phone call/e-mail. As a result, the companion animal vaccine market is experiencing a slight short-term negative impact, owing to lower veterinary visits during COVID-19. Thus, COVID-19 is expected to impact the porcine vaccine market slightly.

Additionally, the growing R&D activities by the key players for discovering novel porcine vaccines to treat diseases and rising product approvals are expected to aid in the positive growth of the studied market over the forecast period. For instance, in May 2021, the Classical Swine Fever (CSF) vaccine was launched under the Raksha Class by Indian Immunologicals Limited (IIL) brand name. Thus, rising product launches anticipated market growth over the forecast period.

According to the Congress Budget Office report in April 2021, the pharmaceutical industry spent USD 83 billion on research and development. These costs were paid for various activities, including discovering and testing new drugs, developing incremental innovations like product extensions, and conducting clinical trials for safety monitoring or marketing purposes. Thus rising in R&D spending boosts the market over the forecast period.

PRRS (Porcine Reproductive and Respiratory Syndrome) is still a common disease in pig farms, causing financial losses due to its adverse effects on reproduction, growth, and clinical illness. As a result, market innovation to meet customer demand has been ongoing. For example, in April 2021, Ahmedabad-based company Hester Bioscience got the right to commercially produce classical swine fever and sheep pox vaccines in India. Scientists develop these two vaccines from the Indian Veterinary Research Institute (IVRI), Izatnagar, under the Indian Council of Agricultural Research (ICAR). Also, in April 2021, the Argentine laboratory Vetanco partnered with Pharmgate Animal Health to distribute the Circo/MycoGard vaccine in Argentina and Latin America. The vaccine protects pigs against both PCV-2 and Mycoplasma hyopneumoniae.

Thus, owing to the abovementioned factors, the market is expected to show growth over the forecast period. However, high expenses of maintaining and handling storage conditions and chance of reverse reaction from vaccines significantly hinder the market's growth.

Porcine Vaccines Industry Segmentation

Porcine Vaccines are a clinical and administrative drug that ameliorates swine health by protecting them from various bacteria, viruses, and other pathogens. The market is segmented by Target Disease (Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Associated Disease (PCVAD), Other Target Diseases), Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Others), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.

By Target Disease
Diarrhea
Swine Influenza
Arthritis
Bordetella Rhinitis
Porcine Reproductive and Respiratory Syndrome (PRRS)
Porcine Circovirus Associated Disease (PCVAD)
Other Target Diseases
By Technology
Inactivated Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Recombinant Vaccines
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Porcine Vaccine Market Size Summary

The porcine vaccines market is poised for substantial growth over the forecast period, driven by increasing pork consumption, the prevalence of swine diseases, and rising animal healthcare expenditure. The market is characterized by a competitive landscape with major players such as Zoetis, Boehringer Ingelheim, and Elanco Inc. These companies are actively engaged in research and development to introduce novel vaccines, addressing diseases like Porcine Reproductive and Respiratory Syndrome (PRRS) and Porcine Circovirus (PCV). Technological advancements in vaccine development, including live vector and nucleic acid-mediated vaccines, are further propelling market expansion, particularly in regions like the United States, where a well-established healthcare infrastructure supports these innovations.

Despite the challenges posed by the COVID-19 pandemic, which temporarily shifted focus away from veterinary research, the porcine vaccine market has shown resilience. The pandemic's impact was mitigated by strategic measures taken by veterinary clinics and hospitals to continue providing services. The market's growth is also supported by regulatory approvals and product launches, such as the Circumvent CML vaccine by Merck Animal Health. However, high storage costs and potential vaccine reactions remain hurdles. Overall, the market is expected to experience significant growth, fueled by ongoing R&D activities, strategic partnerships, and the increasing importance of food safety in emerging economies.

Explore More

Global Porcine Vaccine Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growth in Demand for Pork and Gelatin

      2. 1.2.2 Rise in Prevalence of Swine Diseases

      3. 1.2.3 Increase in R&D Expenditure for Innovation of Vaccines

    3. 1.3 Market Restraints

      1. 1.3.1 High Expenses of Maintaining and Handling Storage Conditions

      2. 1.3.2 Chance of Reverse Reaction from Vaccines

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Target Disease

      1. 2.1.1 Diarrhea

      2. 2.1.2 Swine Influenza

      3. 2.1.3 Arthritis

      4. 2.1.4 Bordetella Rhinitis

      5. 2.1.5 Porcine Reproductive and Respiratory Syndrome (PRRS)

      6. 2.1.6 Porcine Circovirus Associated Disease (PCVAD)

      7. 2.1.7 Other Target Diseases

    2. 2.2 By Technology

      1. 2.2.1 Inactivated Vaccines

      2. 2.2.2 Live Attenuated Vaccines

      3. 2.2.3 Toxoid Vaccines

      4. 2.2.4 Recombinant Vaccines

      5. 2.2.5 Others

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Porcine Vaccine Market Size FAQs

The Global Porcine Vaccine Market size is expected to reach USD 2.05 billion in 2024 and grow at a CAGR of 7.5% to reach USD 2.95 billion by 2029.

In 2024, the Global Porcine Vaccine Market size is expected to reach USD 2.05 billion.

Porcine Vaccines Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)